热门资讯> 正文
Milestone Pharmaceuticals在定价5250万美元后暴跌
2025-07-11 22:41
- Milestone Pharmaceuticals (NASDAQ:MIST) shares fell nearly 38% on Friday after the company priced an offering to raise approximately $52.5 million.
- The offering includes 31.5 million common shares with accompanying Series A and Series B warrants to purchase the same number of shares, at a combined price of $1.50 per share and warrants. Additionally, the offering includes 3,502,335 pre-funded warrants, with accompanying Series A and B warrants, priced at $1.499 each.
- Milestone plans to use the net proceeds, together with existing cash and cash equivalents, to fund the clinical development and commercial launch of etripamil in its lead indication of paroxysmal supraventricular tachycardia, as well as for working capital and other general corporate purposes.
- Source: Press Release
More on Milestone Pharmaceuticals
- Watch Milestone Pharmaceuticals For (Likely) Upcoming FDA Approval For Cardamyst
- Milestone says heart disorder therapy under FDA review again
- Milestone Pharmaceuticals proposes capital raise via securities offering
- Seeking Alpha’s Quant Rating on Milestone Pharmaceuticals
- Historical earnings data for Milestone Pharmaceuticals
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
